0000899243-23-009182.txt : 20230320 0000899243-23-009182.hdr.sgml : 20230320 20230320203101 ACCESSION NUMBER: 0000899243-23-009182 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20230316 FILED AS OF DATE: 20230320 DATE AS OF CHANGE: 20230320 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Klee Justin B. CENTRAL INDEX KEY: 0001898314 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-41199 FILM NUMBER: 23747649 MAIL ADDRESS: STREET 1: C/O AMYLYX PHARMACEUTICALS, INC. STREET 2: 43 THORNDIKE STREET CITY: CAMBRIDGE STATE: MA ZIP: 02141 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Amylyx Pharmaceuticals, Inc. CENTRAL INDEX KEY: 0001658551 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 464600503 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 43 THORNDIKE STREET CITY: CAMBRIDGE STATE: MA ZIP: 02141 BUSINESS PHONE: 617-683-0917 MAIL ADDRESS: STREET 1: 43 THORNDIKE STREET CITY: CAMBRIDGE STATE: MA ZIP: 02141 4 1 doc4.xml FORM 4 SUBMISSION X0407 4 2023-03-16 0 0001658551 Amylyx Pharmaceuticals, Inc. AMLX 0001898314 Klee Justin B. C/O AMYLYX PHARMACEUTICALS, INC. 43 THORNDIKE STREET CAMBRIDGE MA 02141 1 1 0 0 Co-Chief Executive Officer 0 Common Stock 2023-03-16 4 S 0 96555 31.8405 D 2796062 D Common Stock 2023-03-16 4 S 0 3445 32.4751 D 2792617 D Common Stock 2023-03-16 4 A 0 50000 0.00 A 2842617 D Stock Option (right to buy) 32.08 2023-03-16 4 A 0 225000 0.00 A 2033-03-16 Common Stock 225000 225000 D These sales were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on November 15, 2022. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $31.32 to $32.31. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $32.33 to $32.93. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. The reported transaction involves the Reporting Person's receipt of a restricted stock unit award (a "RSU"). The RSU shall vest in 4 equal annual installments, with the first installment vesting on the first day of the month of the one year anniversary of the date of grant, subject to the Reporting Person's continued service to the Issuer through such vesting date. 1/4 of the shares subject to the option shall vest and become exercisable on the first day of the month of the one year anniversary of the date of grant, and the remaining shares shall vest monthly over the remaining 36 months, subject to the Reporting Person's continuous service to the Issuer through such vesting date. /s/ Joshua B. Cohen, as Attorney in Fact 2023-03-20